核心观点创新药放量叠加出海提速，驱动业绩高质量增长。公司2025前三季度实现营收231.88亿元，同比+14.85%，归母净利润57.51亿元，同比+24.50%。Q3单季度实现营收74.27亿元，同比+12.72%，归母净利润13.01亿元，同比+9.53%。业绩高速增长主要来自于两方面：第一，创新药研发成果持续兑现，核心产品市场渗透率提升；第二，对外授权合作加速，首付款及里程碑收益贡献增量业绩...
Source Link核心观点创新药放量叠加出海提速，驱动业绩高质量增长。公司2025前三季度实现营收231.88亿元，同比+14.85%，归母净利润57.51亿元，同比+24.50%。Q3单季度实现营收74.27亿元，同比+12.72%，归母净利润13.01亿元，同比+9.53%。业绩高速增长主要来自于两方面：第一，创新药研发成果持续兑现，核心产品市场渗透率提升；第二，对外授权合作加速，首付款及里程碑收益贡献增量业绩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.